Made-to-measure medicine: BRCA and gynaecological cancer
Mené sur 165 patientes atteintes d'un cancer séreux de l'ovaire sensible aux sels de platines, cet essai de phase II évalue l'efficacité, du point de vue de la survie sans progression et en fonction de la présence d'une mutation du gène BRCA, et la toxicité de l'olaparib, un inhibiteur de PARP, en traitement d'entretien
20 years have passed since the discovery of the major breast cancer susceptibility gene, BRCA1 . Extraordinary progress has been made in the understanding of how BRCA1 and its associated proteins function, and the clinical consequences of malfunctioning BRCA proteins are now evident. The initial concerns about the risks of genetic testing for women carrying mutations in BRCA1 and BRCA2 seem to have receded. Moreover, the recent ruling by the US Supreme Court that genes are not patentable has opened ...
The Lancet Oncology , commentaire, 2013